Literature DB >> 24527807

1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)indoline-4-carbonitrile derivatives as potent and tissue selective androgen receptor modulators.

Eugene L Piatnitski Chekler1, Rayomond Unwalla, Taukeer A Khan, Raghuram S Tangirala, Mark Johnson, Michael St Andre, James T Anderson, Thomas Kenney, Sue Chiparri, Chris McNally, Edward Kilbourne, Catherine Thompson, Sunil Nagpal, Gregory Weber, Scott Schelling, Jane Owens, Carl A Morris, Dennis Powell, Patrick R Verhoest, Adam M Gilbert.   

Abstract

We present a novel series of selective androgen receptor modulators (SARMs) which shows excellent biological activity and physical properties. 1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)-indoline-4-carbonitriles showed potent binding to the androgen receptor (AR) and activated AR-mediated transcription in vitro. Representative compounds demonstrated diminished activity in promoting the intramolecular interaction between the AR carboxyl (C) and amino (N) termini. This N/C-termini interaction is a biomarker assay for the undesired androgenic responses in vivo. In orchidectomized rats, daily administration of a lead compound from this series showed anabolic activity by increasing levator ani muscle weight. Importantly, minimal androgenic effects (increased tissue weights) were observed in the prostate and seminal vesicles, along with minimal repression of circulating luteinizing hormone (LH) levels and no change in the lipid and triglyceride levels. This lead compound completed a two week rat toxicology study, and was well tolerated at doses up to 100 mg/kg/day, the highest dose tested, for 14 consecutive days.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24527807     DOI: 10.1021/jm401625b

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.

Authors:  Michael D Nyquist; Lisa S Ang; Alexandra Corella; Ilsa M Coleman; Michael P Meers; Anthony J Christiani; Cordell Pierce; Derek H Janssens; Hannah E Meade; Arnab Bose; Lauren Brady; Timothy Howard; Navonil De Sarkar; Sander B Frank; Ruth F Dumpit; James T Dalton; Eva Corey; Stephen R Plymate; Michael C Haffner; Elahe A Mostaghel; Peter S Nelson
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 14.808

2.  Synthesis of Aryl Propionamide Scaffold Containing a Pentafluorosulfanyl Moiety as SARMs.

Authors:  Pingxuan Shao; Yan Zhou; Dehua Yang; Ming-Wei Wang; Wei Lu; Jiyu Jin
Journal:  Molecules       Date:  2019-11-20       Impact factor: 4.411

3.  Synthesis and preclinical validation of novel P2Y1 receptor ligands as a potent anti-prostate cancer agent.

Authors:  Hien Thi Thu Le; Tatu Rimpilainen; Saravanan Konda Mani; Akshaya Murugesan; Olli Yli-Harja; Nuno R Candeias; Meenakshisundaram Kandhavelu
Journal:  Sci Rep       Date:  2019-12-12       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.